Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: A potential therapeutic role

Biochemical Pharmacology

Volumn 79, Issue 2, 2010, Pages 198-208

  Martín, Rubén ^a   Carvalho Tavares, Juliana ^a   Hernández, Marita ^a   Arnés, Mercedes ^a   Ruiz Gutiérrez, Valentina ^b   Nieto, María Luisa ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b INSTITUTO DE LA GRASA   (Spain)

Author keywords

Encephalomyelitis; Inflammation; Neuroimmunology; Pharmacology; Triterpenes

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; OLEANOLIC ACID; TRITERPENE DERIVATIVE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EARLY INTERVENTION; EXPERIMENTAL MODEL; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LIQUORRHEA; MOUSE; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROPHARMACOLOGY; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODY FORMATION; BLOOD-BRAIN BARRIER; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE SCLEROSIS; OLEANOLIC ACID;

EID: 71749084656     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.002     Document Type: Article

References (45)

1. Hemmer B., Archelos J.J., and Hartun H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3 (2002) 291-301
2. Cannella B., and Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37 (1995) 424-425
3. Muller D.M., Pender M.P., and Greer J.M. Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. J Neuroimmunol 60 (2005) 162-169
4. Benveniste E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75 (1997) 165-173
5. Karpus W.J., and Ransohoff R.M. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol 161 (1998) 2667-2671
6. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 70 (2007) 461-477
7. Liu J. Oleanolic and ursolic acid: research perspectives. J Ethnopharm 100 (2005) 92-94
8. Dzubak P., Hajduch M., Vydra D., Hustova A., Kvasnica M., Biedermann D., et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 23 (2006) 394-411
9. Perez-Jimenez F., Alvarez de Cienfuegos G., Badimon L., Barja G., Battino M., Blanco A., et al. International conference on the healthy effect of virgin olive oil. Eur J Clin Invest 35 (2005) 421-424
10. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49 (1995) 57-68
11. Yim T.K., Wu W.K., Pak W.F., and Ko K.M. Hepatoprotective action of an oleanolic acid-enriched extract of Ligustrum lucidum fruits is mediated through an enhancement on hepatic glutathione regeneration capacity in mice. Phytother Res 15 (2001) 589-592
12. Raphael T.J., and Kuttan G. Effect of naturally occurring triterpenoids glycyrrhizic acid, ursolic acid, oleanolic acid and nomilin on the immune system. Phytomedicine 10 (2003) 483-489
13. Liby K.T., Yore M.M., and Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7 (2007) 357-369
14. Liu Q., Garner P., Wang Y., Huang B., and Smith H. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 8 (2008) 365
15. Choi W, Han CK, Kim TK, Im GJ, Jung CM, Yun SJ, et al. Triterpene compounds which are effective on improvement of brain function. 2005 Patent Application: WO/2005/034958.
16. Tran T.A., McCoy M.K., Sporn M.B., and Tansey M.G. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation 5 (2008) 14
17. Guinda A., Albi T., Perez-Camino M.C., and Lanzon A. Supplementation oils with oleanolic acid from the olive leaf (Olea europaea). Eur J Lipid Sci Technol 106 (2004) 22-26
18. Baatz H., Steinbauer M., Harris A.G., and Krombach F. Kinetics of white blood cell staining by intravascular administration of rhodamine 6G. Int J Microcirc Clin Exp 15 (1995) 85-91
19. Carvalho-Tavares J., Hickey M.J., Hutchison J., Michaud J., Sutcliffe I.T., and Kubes P. A role for platelets and endothelial selectins in tumor necrosis factor induced leukocyte recruitment in the brain microvasculature. Circ Res 87 (2000) 1141-1148
20. Senthil S., Chandramohan G., and Pugalendi K.V. Isomers (oleanolic and ursolic acids) differ in their protective effect against isoproterenol-induced myocardial ischemia in rats. Int J Cardiol 119 (2007) 131-133
21. Jeong H.G. Inhibition of cytochrome P450 2E1 expression by oleanolic acid: hepatoprotective effects against carbon tetrachloride-induced hepatic injury. Toxicol Lett 105 (1999) 215-222
22. Marquez-Martin A., De La Puerta R., Fernandez-Arche A., Ruiz-Gutierrez V., and Yaqoob P. Modulation of cytokine secretion by pentacyclic triterpenes from olive pomace oil in human mononuclear cells. Cytokine 36 (2006) 211-217
23. Imitola J., Chitnis T., and Khoury S. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Therap 106 (2005) 163-177
24. Mocellin S., Panelli M.C., Wang E., Nagerson D., and Marincola F.M. The dual role of IL-10. Trends Immunol 24 (2003) 36-43
25. McClain M.A., Gatson N.N., Powell N.D., Papenfuss T.L., Gienapp I.E., Song F., et al. Pregnancy suppresses experimental autoimmune encephalomyelitis through immunoregulatory cytokine production. J Immunol 179 (2007) 8146-8152
26. Jansson M., Panoutsakopoulou V., Baker J., Klein L., and Cantor H. Attenuated experimental autoimmune encephalomyelitis in Eta-1/osteopontin-deficient mice. J Immunol 168 (2002) 2096-2099
27. Sharief M.K., and Thompson E.J. In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 38 (1992) 27-34
28. Megyeri P., Abraham C., Temesvari P., Kovas J., Vas T., and Speer C. Recombinant human tumor necrosis factor constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets. Neurosci Lett 148 (1992) 137-140
29. Scott G.S., Kean R.B., Fabis M.J., Mikheeva T., Brimer C.M., Phares T.W., et al. ICAM-1 upregulation in the spinal cords of PLSJL mice with experimental allergic encephalomyelitis is dependent upon TNF-alpha production triggered by the loss of blood-brain barrier integrity. J Neuroimmunol 155 (2004) 32-42
30. Royall J.A., Berkow R.L., Beckman J.S., Cunningham M.K., Matalon S., et al. Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257 (1989) L399-10
31. Gijbels K., Galardy R.E., and Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94 (1994) 2177-2182
32. Ohnishi T., Posner J.B., and Shapiro W.R. Vasogenic brain edema induced by arachidonic acid: role of extracellular arachidonic acid in blood-brain barrier dysfunction. Neurosurgery 30 (1992) 545-551
33. Kean R.B., Spitsin S.V., Mikheeva T., Scott G.S., and Hooper D.C. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 165 (2000) 6511-6518
34. Paul C., and Bolton C. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-Methyl-d-aspartate receptor antagonist memantine. J Pharmacol Exp Ther 302 (2002) 50-57
35. Fabis M.J., Phares T.W., Kean R.B., Koprowski H., and Hooper D.C. Blood-brain barrier changes and cell invasion differ between therapeutic immuneclearance of neurotrophic virus and CNS autoimmunity. Proc Natl Acad Sci USA 105 (2008) 15511-15516
36. Son I.H., Park Y.H., Lee S.I., Yang H.D., and Moon H. Neuroprotective activity of triterpenoid saponins from Platycodi radix against glutamate-induced toxicity in primary cultured rat cortical cells. Molecules 12 (2007) 1147-1152
37. Shen Y.H., Weng Z.Y., Zhao Q.S., Zeng T.Q., Rios J.L., Xiao W.L., et al. Five new triterpene glycosides from Lysimachia foenum-graecuma and evaluation of their effect on the arachidonic acid metabolizing enzyme. Planta-Med 71 (2005) 770-775
38. Fu L., Zhang S., Li N., Wang J., Zhao M., Sakai J., et al. Three new triterpenes from Nerium oleander and biological activity of the isolated compounds. J Nat Prod 68 (2005) 198-206
39. Linington C., Bradl M., Lassmann H., Brunner C., and Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130 (1988) 443-454
40. McQualtera J.L., Darwicheb R., Ewinga C., Onukia M., Kayb T.W., Hamiltonc J.A., et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 194 (2001) 873-882
41. Bischof F., Bins A., Dürr M., Zevering Y., Melms A., and Kruisbeek A.M. A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response. J Immunol 173 (2004) 600-606
42. Mujtaba M.G., Streit W.J., and Johnson H.M. IFN-tau suppresses both the autoreactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis. Cell Immunol 186 (1998) 94-102
43. Palazuelos J., Davoust N., Julien B., Hatterer E., Aguado T., Mechoulam R., et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 283 (2008) 13320-13329
44. Arévalo-Martín A., García-Ovejero D., Gómez O., Rubio-Araiz A., Navarro-Galve B., Guaza C., et al. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br J Pharmacol 153 (2008) 216-225
45. Sánchez A.J., González-Pérez P., Galve-Roperh I., and García-Merino A. R-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1 naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem Pharmacol 72 (2006) 1697-1706